Epidaza Application Scope

Epidaza® (Chidamide Tablets) is indicated for the treatment of relapsed or refractory Peripheral T-Cell Lymphoma (PTCL) in adult patients who have received prior systemic therapy.

Epidaza Characteristics

Ingredients: Chidamide
Properties: Film-coated tablet
Packaging Specification: Specific packaging may vary by region and batch
Storage: Store below 25°C (77°F). Protect from light and moisture. Keep the blister in the outer carton
Expiry Date: 24 or 36 months from the date of manufacture
Executive Standard: National Drug Standard of the People’s Republic of China
Approval Number: National Medical Products Administration (NMPA) Approval Number: H20140129
Date of Revision: Refer to the latest approved package insert
Manufacturer: Shenzhen Chipscreen Biosciences Co., Ltd.

Guidelines for the Use of Epidaza

Dosage and Administration:
- Recommended Dose:
  - 30 mg, taken twice weekly
  - Doses should be administered with at least 72 hours between doses
- Administration:
  - Oral administration
  - Tablets should be swallowed whole with water
  - May be taken with or without food
- Missed Dose:
  - If a dose is missed, do not take an extra dose
  - Resume the regular dosing schedule as prescribed
Adverse Reactions:
- Common Adverse Reactions:
  - Thrombocytopenia
  - Neutropenia
  - Anemia
  - Fatigue
  - Nausea
  - Diarrhea
  - Decreased appetite
- Serious Adverse Reactions:
  - Severe myelosuppression
  - Serious infections
  - Significant bleeding related to thrombocytopenia
Contraindications:
- Known hypersensitivity to chidamide or any excipients
- Use with caution in patients with severe hepatic impairment
Precautions:
- Regular monitoring of blood counts is recommended
- Dose adjustment may be required in cases of hematologic toxicity
- Use with caution in patients with infection risk
- Safety in pregnancy and lactation has not been established

Epidaza Interactions

Caution when used concomitantly with other myelosuppressive agents
Potential interactions with drugs affecting hepatic metabolism
Always inform healthcare providers of all concomitant medications

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.